Cooley Advises Xencor on its Initial Public Offering

Palo Alto, Calif. – December 10, 2013 – Cooley LLP announced today that it advised Xencor, Inc. on its initial public offering. Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, now trades on the NASDAQ Global Market under the symbol "XNCR."

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 700 lawyers across eleven offices in the United States and China.

Related Contacts
Tom Coll  Partner San Diego
Ken Rollins  Partner San Diego
Megan Arthur Schilling  Partner San Diego
Natasha Leskovsek  Of Counsel Washington, DC
Karen Deschaine  Partner San Diego
Kristin VanderPas  Partner San Francisco
Terren O'Connor  Associate San Diego